Functional Imaging and Reading Deficit in Children With NF1
- Conditions
- Neurofibromatosis Type 1
- Registration Number
- NCT02422732
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
A monocenter pilot study on the acceptability and feasibility of a functional MRI protocol in children with NF1 with or without reading disabilities.
- Detailed Description
The principal aim of the study is to highlight the activation of brain area involved phonological and visuo-spatial processing in children with NF1 with or without reading disabilities.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 25
-
Age included between 8 and 12 years
-
Child presenting a type 1 neurofibromatosis according to 2 criteria in the following criteria list :
- At least 6 café au lait spots
- 2 or more neurofibromas or 1 plexiform neurofibroma
- axillary or inguinal freckling
- 1 optic nerf glioma
- 2 or more Lisch nodules
- 1 osseous lesion as sphenoid dysplasia or thinning of the long bone cortex with or without pseudarthrosis
- 1 A first degree relative (parent, sibling, or offspring) with NF1 by the above criteria
-
Membership in a national insurance
-
Consent of the child and the parents
- Mental retardation (QI T < 70)
- Treated or untreated epilepsy
- Visual deficit (visual Acuteness < 4/10
- Presence of a symptomatic optic glioma
- Presence of a brain tumor.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Percentage of children performing in full the protocol functional MRI day 1 Study the acceptability and feasibility of a functional MRI protocol in children with NF1 with or without reading disabilities.
- Secondary Outcome Measures
Name Time Method blood flow in milliliters per minute day 1 Comparison of brain activations involved in phonological and visuo-spatial processing in 2 groups in children with NF1.
1 group with reading disability and 1 group without reading disability Search for a link between the presence of a large deletion of the gene and learning disorders.
Trial Locations
- Locations (1)
CHU Toulouse
🇫🇷Toulouse, France
CHU Toulouse🇫🇷Toulouse, France